Synflorix Suspension for Injection (Prefilled Syringe)
Product details
Registration number: SIN13775P
Classification: Prescription Only
Active ingredients:
- Conjugate of Streptococcus pneumoniae type 1 & Haemophilus influenzae protein D
- Conjugate of Streptococcus pneumoniae type 14 and Haemophilus influenzae protein D
- Conjugate of Streptococcus pneumoniae type 18C and tetanus toxoid
- Conjugate of Streptococcus pneumoniae type 19F and diphtheria toxoid
- Conjugate of Streptococcus pneumoniae type 23F and Haemophilus influenzae protein D
- Conjugate of Streptococcus pneumoniae type 4 and Haemophilus influenzae protein D
- Conjugate of Streptococcus pneumoniae type 5 and Haemophilus influenzae protein D
- Conjugate of Streptococcus pneumoniae type 6B and Haemophilus influenzae protein D
- Conjugate of Streptococcus pneumoniae type 7F and Haemophilus influenzae protein D
- Conjugate of Streptococcus pneumoniae type 9V and Haemophilus influenzae protein D
- Diphtheria Toxoid (DT) Carrier Protein
- Polysaccharide (PS)
- Protein-D (PD) Carrier Protein (derived from non-typeable Haemophilus influenzae)
- Tetanus Toxoid (TT) Carrier Protein
Strength:
- 1 μg PS1; 1.11-1.67 μg PD/dose
- 1 μg PS14; 1.00-1.82 μg PD/dose
- 3 μg PS18C; 5.45-10.00 μg TT/dose
- 3 μg PS19F; 3.33-6.00 μg DT/dose
- 1 μg PS23F; 0.39-0.74 μg PD/dose
- 3 μg PS4; 3.33-6.67 μg PD/dose
- 1 μg PS5; 0.67-1.25 μg PD/dose
- 1 μg PS6B; 0.56-0.95 μg PD/dose
- 1 μg PS7F; 0.87-1.43 μg PD/dose
- 1 μg PS9V; 1.00-1.82 μg PD/dose
- 3-6 μg DT/dose (total DT content)
- 16 μg/dose (total PS content)
- 9-16 μg PD/dose (total PD content)
- 5-10 μg/dose (total TT content)
Dosage form: INJECTION, SUSPENSION
Route: INTRAMUSCULAR
Registrant: GLAXOSMITHKLINE PTE LTD
ATC code: J07AL52
HSA approval date: 19 March 2010
Manufacturer(s):
- GlaxoSmithKline Biologicals SA (Filling)
- GlaxoSmithKline Biologicals SAS
Manufacturing country/countries: BELGIUM; FRANCE
What are the HSA registration number and classification for Synflorix Suspension for Injection (Prefilled Syringe)?
According to the HSA dataset updated 7 August 2026:
Registration number: SIN13775P
Classification: Prescription Only
What active ingredients and strength are recorded for Synflorix Suspension for Injection (Prefilled Syringe)?
According to the HSA dataset updated 7 August 2026:
Active ingredients:
- Conjugate of Streptococcus pneumoniae type 1 & Haemophilus influenzae protein D
- Conjugate of Streptococcus pneumoniae type 14 and Haemophilus influenzae protein D
- Conjugate of Streptococcus pneumoniae type 18C and tetanus toxoid
- Conjugate of Streptococcus pneumoniae type 19F and diphtheria toxoid
- Conjugate of Streptococcus pneumoniae type 23F and Haemophilus influenzae protein D
- Conjugate of Streptococcus pneumoniae type 4 and Haemophilus influenzae protein D
- Conjugate of Streptococcus pneumoniae type 5 and Haemophilus influenzae protein D
- Conjugate of Streptococcus pneumoniae type 6B and Haemophilus influenzae protein D
- Conjugate of Streptococcus pneumoniae type 7F and Haemophilus influenzae protein D
- Conjugate of Streptococcus pneumoniae type 9V and Haemophilus influenzae protein D
- Diphtheria Toxoid (DT) Carrier Protein
- Polysaccharide (PS)
- Protein-D (PD) Carrier Protein (derived from non-typeable Haemophilus influenzae)
- Tetanus Toxoid (TT) Carrier Protein
Strength:
- 1 μg PS1; 1.11-1.67 μg PD/dose
- 1 μg PS14; 1.00-1.82 μg PD/dose
- 3 μg PS18C; 5.45-10.00 μg TT/dose
- 3 μg PS19F; 3.33-6.00 μg DT/dose
- 1 μg PS23F; 0.39-0.74 μg PD/dose
- 3 μg PS4; 3.33-6.67 μg PD/dose
- 1 μg PS5; 0.67-1.25 μg PD/dose
- 1 μg PS6B; 0.56-0.95 μg PD/dose
- 1 μg PS7F; 0.87-1.43 μg PD/dose
- 1 μg PS9V; 1.00-1.82 μg PD/dose
- 3-6 μg DT/dose (total DT content)
- 16 μg/dose (total PS content)
- 9-16 μg PD/dose (total PD content)
- 5-10 μg/dose (total TT content)
Ingredients and strengths are listed separately as recorded by HSA; their positions do not establish a one-to-one match. This is not a dosing instruction.
What dosage form and route are recorded for Synflorix Suspension for Injection (Prefilled Syringe)?
According to the HSA dataset updated 7 August 2026:
Dosage form: INJECTION, SUSPENSION
Route: INTRAMUSCULAR
Who is the recorded registrant for Synflorix Suspension for Injection (Prefilled Syringe)?
According to the HSA dataset updated 7 August 2026:
Registrant: GLAXOSMITHKLINE PTE LTD
Which manufacturers and countries are listed for Synflorix Suspension for Injection (Prefilled Syringe)?
According to the HSA dataset updated 7 August 2026:
Manufacturer(s):
- GlaxoSmithKline Biologicals SA (Filling)
- GlaxoSmithKline Biologicals SAS
Manufacturing country/countries: BELGIUM; FRANCE
Where can I look up Synflorix Suspension for Injection (Prefilled Syringe) in the HSA register?
Open HSA’s therapeutic product register and search for registration number SIN13775P or the exact product name Synflorix Suspension for Injection (Prefilled Syringe). The general register link does not preselect this product.
What are the source dates for this Synflorix Suspension for Injection (Prefilled Syringe) record?
This record is from HSA’s List of Registered Therapeutic Products on data.gov.sg. Dataset update: 7 August 2026. Retrieval date: 13 November 2026.
The dataset date is a snapshot date, not a separate current-register check for every product. Later direct checks are recorded separately.
Has this Synflorix Suspension for Injection (Prefilled Syringe) record had a separate HSA register check?
No separate current-register check is recorded for this product. Its presence in the imported dataset does not establish its current registration status.
Search the HSA register using SIN13775P for the latest record.
Sources and dates
HSA dataset: 2026. Updated: 13 November 2026.
Factual product information only; no dosing, treatment or suitability advice.
Updated and reviewed by: Dr Joel Lim MBChB UK (PG Dip Dermatology), Resident Physician.
.png)